JAK2 and breast carcinoma: Since STAT3 phosphorylation inhibition was consistent with inhibiting in vivo breast cancer cell development by nifuroxazide [49], in our opinion, modulation of the Jak2/STAT3 signaling pathway by nifuroxazide declares the availability of drug-combination options that is matched with [50], who studied that phytocompounds target the JAK/STAT signaling pathway for cancer therapy.